| INTRODUCTION
Tryptase, the most abundant product of human mast cells, is emerging as a key mediator of inflammation, as well as being an important marker for mast cell activation in allergic disease. Although relatively few naturally occurring substrates have been identified for this tetrameric serine protease, a range of potent pro-inflammatory actions has been described for tryptase following its administration into animal models, or when it is transferred to cells or tissues. Reports that tryptase can activate protease-activated receptor 2 (PAR2) [1] [2] [3] have led to suggestions that this G protein-coupled receptor may represent a key cellular target. [4] [5] [6] [7] Tryptase can like certain other tryptic proteases cleave PAR2 to expose a "tethered ligand" leading to signal transduction. The idea that PAR2 has a pivotal role in mediating the actions of tryptase has received support from comparisons of the actions of PAR2 agonists with those of tryptase. However, some discrepancies have been reported, raising questions over the degree to which PAR2 activation may be involved. 2, 8, 9 Transfer of purified human tryptase into the peritoneum 10 or trachea of mice, 11 or the skin of guinea-pigs 12 or sheep, 13 has been found to stimulate massive accumulation of neutrophils or eosinophils, and, in some cases, prolonged microvascular leakage. Peritoneal injection of the mouse tryptase mMCP-6 is also associated with intraperitoneal neutrophilia, 14 while injection with mMCP-7,
another mouse tryptase, has induced eosinophil accumulation in the peritoneal cavity. 11 In all in vivo models studied, the actions of tryptase have been dependent on an intact catalytic site, and inhibitors of tryptase have shown efficacy in models of asthma in sheep, 15 mice 16 and humans, 17, 18 as well as in a rat model of colitis. 19 Transfer of peptide agonists of PAR2 such as SLIGRL-NH 2 in vivo has also been associated with induction of microvascular leakage and neutrophilia, [20] [21] [22] although paradoxically there have been reports also of anti-inflammatory actions in vivo. 23 Tryptase has been demonstrated to induce profound changes in the behaviour of various cell types including mast cells, neutrophils, eosinophils, endothelial cells, airway smooth muscles and several cell lines. Tryptase can induce the degranulation of human mast cells 12 and eosinophils 24 and induce mitogenic responses and cytokine release from endothelial cells, 25 epithelial cells 26 and airway smooth muscle cells. 27, 28 These cell types express PAR2, and in most cases, effects similar to those for tryptase have been found to be elicited also by PAR2 agonists 24, [29] [30] [31] [32] ; and cell signalling responses described in some cell models have been similar with both tryptase and PAR2
agonists. 33, 34 A lack of effective PAR2 antagonists has hindered their application in such studies, although the peptide antagonist FSLLRY-NH 2 has been reported to reverse some of the cell signalling responses of tryptase in cells. 29, 35 There have been relatively few direct comparisons between tryptase and other potential PAR2 agonists, but peptide agonists of PAR2 have failed to elicit certain actions of tryptase such as stimulation of IL-8 release from airway smooth muscle cells, 36 or the degranulation of lung mast cells 37 and eosinophils. 24 The advent of PAR2 knockout mice with C57BL/6J background (which are apparently phenotypically normal) in which lack of PAR2 functionality has been demonstrated [38] [39] [40] has provided evidence for a key role for this receptor in disease. These have included models for studying the spread of melanoma metastases 39 and joint swelling in arthritis. 38, 40 While intra-articular injection of tryptase has been reported to stimulate joint swelling and hyperaemia in wild-type mice, it failed to do so in PAR2 knockout mice suggesting that there is a dependence on PAR2 activation, but detailed investigation of cellular changes or other features of inflammation was not examined.
In this study, we have demonstrated that tryptase is able to stimulate inflammatory cell accumulation, microvascular leakage and gelatinase release in the peritoneum of both wild-type and PAR2-deficient mice models. Our findings cast doubt on PAR2 having a key role in mediating these changes.
| MATERIALS AND METHODS

| Preparation and purification of tryptase
Tryptase was isolated from a Pichia pastoris expression system for bII-tryptase following protocols similar to those described by Niles et al, 41 with sequential purification by hydrophobic interaction chromatography followed by heparin affinity chromatography. ) or a peptide with the same amino acids but with a "scrambled" sequence (LSIGRL-NH 2 ; 1 lg mL
À1
).
Tryptase was handled with care to avoid loss of enzymatic activity and was kept on ice and diluted with saline immediately before injection of the animal. The degree of enzyme inhibition was assessed spectrophotometrically using the chromogenic substrate
BApNA. Where inadvertent injection or damage to the gut was suspected, such animals were excluded from the study. CaCl 2 ) and then stained with Coomassie blue dye. Gels were photographed using a Molecular Imager GS-800 calibrated densitometer (Bio-Rad Laboratories, Hemel Hempstead, UK), and intensity and size of the bands were determined relative to a positive control for MMP2 and MMP9 activity; a supernatant from the human fibrosarcoma cell line (HT1080) was employed. 44 
| Peritoneal lavage
| Immunomagnetic purification of neutrophils
In order to examine the potential contribution of neutrophils to the response of mice to tryptase, peritoneal cells were collected from naїve mice and from mice which had been injected intraperitoneally with tryptase (0.5 lg/mouse) or casein, an established stimulus for neutrophil accumulation, (0.5 mL of 9% solution/mouse). 45 The casein for injection was prepared as described previously 46 were used for analysis of data and preparation of graphs. P < .05
was taken as significant. Figure 1D ). An apparent segregation of wild-type mice into those with mild (n = 8) or extensive neutrophilia (n = 5) was observed, although neutrophil numbers in each of these subgroups were significantly greater than in the saline-injected control mice (P = .030 and P = .0005, respectively; Mann-Whitney U test). Significant neutrophilia was seen also in the PAR2-deficient mice. There was a trend for increased numbers of neutrophils to be recovered in peritoneum also at 6 and 12 hours, although this reached significance only at 6 hours for the PAR2-deficient mice (data not shown).
Relative numbers of eosinophils, lymphocytes, macrophages and mast cells appeared to be little affected by injection of tryptase at any time-point. There were no significant differences between these two mouse strains in the numbers of other cells types in the peritoneum.
As the pattern of cell accumulation in mice of the C57BL/6 strain differed from that reported previously following injection of human lung tryptase in BALB/c mice, 10 (Table 1) .
| Effect of tryptase on peritoneal gelatinase and elastolytic activity
Peritoneal lavage fluid from saline-injected mice exhibited activity on gelatin zymography, with bands at positions corresponding to those for MMP2 but not for MMP9 (Figure 2A ). Tryptase injection, on the other hand, was associated with the presence of bands in peritoneal lavage fluid for both MMP2 and MMP9. Levels of MMP2 were higher in mice 24 hours following tryptase injection than at 6 and 12 hours and, at this time-point, were significantly greater than in the saline-injected mice ( Figure 2B ). At all of these time-points, MMP9 activity was substantially greater in the tryptase-injected than the saline-injected mice, although levels at 24 hours were greater than at 6 or 12 hours ( Figure 2C ).
Peritoneal lavage fluid MMP2 activity was higher in tryptaseinjected mice deficient in PAR2 than in the corresponding wild-type mice at 12 hours (P < .0001) and 24 hours (P < .005), but not at 6 hours ( Figure 2B ). For the saline-injected mice, there were no apparent strain-related differences in MMP2 levels. For MMP9 activity, there was greater activity in the PAR2 knockout mice than in the wild-type at 12 hours (P < .005), but not at 6 or 24 hours.
Mice injected with heat-inactivated tryptase did not show a marked tryptase-induced increase in MMP2 and MMP9 activity in peritoneal lavage fluid (Table 2) . Median values and interquartile range are shown. *P < .05 **P < .005 ***P < .0001, (MannWhitney U test). n.s., not significant
(E) (F) (G) (I) (H) F I G U R E 1 Eosin/methylene blue-stained cytocentrifuge preparations of cells recovered by peritoneal lavage from C57BL/6 mice 24 hours following injection with (A) tryptase or (B) saline. Examples of neutrophils (N), eosinophils (E), macrophages (M), lymphocytes (L) and mast cells (MC) are indicated. Numbers are indicated of (C) nucleated cells, (D) neutrophils, (E) eosinophils, (F) macrophages, (G) lymphocytes and (H)
In peritoneal lavage fluid, levels of MMP2 and MMP9 activity were closely correlated in both tryptase-injected wild-type mice (r s = .882, n = 33, P < .005) and PAR2-deficient mice (r s = .975, n = 30 P < .005). The activity of MMP2 was associated with the numbers of neutrophils recovered from the peritoneum of wild-type (r s = .335, n = 33, P < .005) and knockout mice (r s = .328, n = 30, P < .005). Similarly, the activity of MMP9 was correlated with the number of neutrophils from both wild-type (r s = .452, n = 33, Median and interquartile range values are shown for 10-12 mice each group. *P < .05 **P < .005 ***P < .0001, compared with response in the salineinjected group. † P < .05 † † P < .005, compared with response in the tryptase-injected group. ND, none detected; -, not tested.
was not observed under similar conditions following injection of the non-PAR2-activating peptide LSIGRL-NH 2 in either the wild-type (1.74, 1.68-1.86) or PAR2-deficient mice (2.11, 2.00-2.30) and, in fact, that in the wild-type mice was actually lower than in salineinjected mice (P = .001). No MMP9 activity was found in any of these mice following the injection of SLIGRL-NH 2 , LSIGRL-NH 2 or saline.
| Identification of neutrophils as source of gelatinase activity
Supernatant from a neutrophil-rich cell population (88% neutrophils)
obtained from the peritoneum of 10 tryptase-injected PAR2
wild-type mice (by positive selection with magnetic beads) had substantially more MMP9 than that from a neutrophil-depleted cell population (12% neutrophils; Figure 3 ). This was observed when cells were incubated in vitro for 1, 6 and 24 hours. There was little MMP2 activity in supernatants of peritoneal cells at any of these time-points. The supernatant of a mixed cell population from caseininjected mice (n = 5) also showed MMP9 activity but that from na€ ıve mice (n = 3) had negligible quantities (data not shown).
Treatment of either neutrophil-rich or neutrophil-depleted cell populations with 6.5 or 13 lg mL À1 (20 or 40 mU mL For both wild-type and PAR2-deficient mice injected with tryptase, at 24 hours, peritoneal lavage fluid histamine levels were lower than in the saline-injected mice. This effect was not seen with heated tryptase or at the earlier time-points with catalytically active tryptase.
| DISCUSSION
The present study confirms and extends the idea that mast cell tryptase has potent pro-inflammatory actions, but suggests that the effects are not mediated through activation of PAR2. Tryptase was a potent stimulus for the accumulation of neutrophils in vivo and induced MMP release and prolonged microvascular leakage. Despite several studies suggesting that the actions of tryptase are mediated by cleavage of PAR2, at least in the present model, the role tryptase as a mediator of inflammation appears to be independent of PAR2.
Care was taken to ensure that the tryptase employed in this study was of high purity and activity, and on SDS-PAGE, recombinant tryptase appeared as a single band whose identity was con- Being present in such increased numbers, the neutrophil deserves consideration as a contributor to the microvascular leakage observed, and this cell is, like the mast cell, an important source of proteases. Neutrophil elastase has been reported to induce an increase in the permeability of monolayers of epithelial cell lines, 51, 52 although, in the present study, elastase could not be detected in the peritoneal lavage fluid by elastin zymography. Stronger evidence in the present model was provided for the presence of neutrophilderived MMP9 which has also been shown to be implicated in stimulating microvascular leakage. 53 The tryptase-induced increases in the number of neutrophils were highly significantly correlated with Heating tryptase or pre-incubating this protease with the selective tryptase inhibitor effectively inhibited tryptase-induced neutrophilia dependence on an intact catalytic site but not the tryptase-induced microvascular leakage. The latter finding may reflect involvement of a non-proteolytic mechanism for tryptase as has been reported previously, 59 or possibly a lack of potency for the inhibitor (which itself stimulated microvascular leakage at the concentration employed). However, the present studies strongly suggest that PAR2 is not a key substrate for tryptase in this model.
Patterns of tryptase-induced inflammatory cell accumulation were similar for both wild-type and PAR2-deficient mice. The PAR2 knockout mice had higher peritoneal lavage levels of MMP2 at 12 and 24 hours, and of MMP9 at 12 hours compared to the wildtype mice, but the differences were relatively small; and there were no differences between these mouse strains in relative concentra- The PAR2 agonist peptide was able to provoke eosinophilia in wild-type (but not in the PAR2-deficient mice), an observation consistent with a report of eosinophil accumulation following intrapleural administration of this peptide in BALB/c mice. 60 However, in our model, injection of LSIGRL-NH 2 , a control peptide without demonstrable actions on PAR2, 61 was also able to stimulate cell accumulation. Biological actions have been noted previously with this peptide, including altered flux of rolling leucocytes in naive rats after superfusion 22 and also calcium mobilization in cultured human endothelial cells (Khedr et al, unpublished data).
Recruitment of polymorphonuclear leucocytes was found following injection of SLIGRL-NH 2 into the peritoneum of rats, 22 but as in our study, it has been reported that this PAR2 agonist did not induce an inflammatory infiltrate when administered into the peritoneum of BALB/c mice. 23, 62 Similarly, administration of SLIGRL-NH 2 into mouse airways failed to induce neutrophilia, and this peptide was found to actually inhibit cell accumulation provoked by LPS. 62 While the greater susceptibility to degradation may be a factor, there is thus little evidence to indicate that SLIGRL-NH 2 can reproduce the actions of tryptase.
The similarity in tryptase-induced inflammatory changes in wildtype and PAR2-deficient mice argues against PAR2 having a key role in mediating the actions of tryptase. The potential of tryptase to activate this receptor has been questioned previously, with Huang et al failing to observe PAR2 activation in vitro following addition of tryptase to cells. 11 The lack of PAR2 activation was attributed to functional heterogeneity in tryptases, and it was suggested that there may be different substrate specificities between the bI-tryptase they employed and the bII-tryptase or lung-derived tryptase that had been employed previously by others to activate PAR2. [1] [2] [3] 20 However, the variant of tryptase employed in the present studies (bII-tryptase) is the same as that described as being able to activate PAR2. 38, 63 The tetrameric structure of tryptase with the catalytic sites positioned within a central pore 64 is likely to restrict access of the extracellular domain of PAR2 as a substrate, and heavy glycosylation of the N-terminal sequence of PAR2 has been reported to prevent tryptase-induced receptor activation. 8 Moreover, tryptase can cleave PAR2 not just at a site that would result in exposure of the tethered ligand, but also at a point that could "disarm" the receptor. insulin-like growth factor-1 receptors), 65 and the release of a membrane tethered agonist, for example, heparin-binding epidermal growth factor (EGF) by metalloproteinases. 66 In theory, also a growth factor agonist could be generated from precursors through proteolytic activity. The ability of tryptase to control the bioavailability of cytokines has been suggested on the basis of the finding that this protease can activate TGFb, and at least in mice, to inactivate IL-6 from mast cells. 28, 67 Unravelling the processes involved will represent a major challenge.
In conclusion, our findings indicate that tryptase is a potent stimulus of inflammation in vivo, and as such deserves attention as a target for therapeutic intervention. At quite low concentrations, this protease can stimulate neutrophilia, microvascular leakage and the generation of MMP9 and MMP2. The studies with PAR2 knockout mice challenge the assumption that activation PAR2 represents the primary mechanism by which tryptase can mediate inflammatory changes. The actions of tryptase were dependent on an intact catalytic site, but in the model employed, the pro-inflammatory actions of tryptase appear to be largely independent of PAR2.
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